Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 14, 2023

Safety and Efficacy of Giredestrant ± Palbociclib ± LHRH Agonists in Patients With ER+/HER2− Locally Advanced/Metastatic Breast Cancer

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Phase Ia/b Study of Giredestrant ±Palbociclib and ±Luteinizing Hormone-releasing Hormone Agonists in Estrogen Receptor-positive, HER2-negative, Locally Advanced/Metastatic Breast Cancer
Clin. Cancer Res 2023 Nov 03;[EPub Ahead of Print], KL Jhaveri, M Bellet-Ezquerra, NC Turner, S Loi, A Bardia, V Boni, J Sohn, TG Neilan, R Villanueva-Vázquez, P Kabos, L García Estévez, E Lopez-Miranda, JA Perez Fidalgo, JM Perez-Garcia, J Yu, J Fredrickson, HM Moore, CW Chang, JW Bond, J Eng-Wong, MR Gates, E Lim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading